Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Pract Res Clin Haematol 2016 Mar;29(1):54-66
Date
10/16/2016Pubmed ID
27742072DOI
10.1016/j.beha.2016.08.001Scopus ID
2-s2.0-84992187395 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
Novel therapies targeting various kinases downstream of the B-cell receptor have emerged along with monoclonal antibodies and BCL-2 antagonists, and are changing the therapeutic landscape of chronic lymphocytic leukemia. However, cure remains unattainable unless eligible patients are offered an allogeneic hematopoietic cell transplant. Access to allogeneic hematopoietic cell transplantation has expanded considerably with availability of reduced intensity conditioning regimens which is capable offering durable remissions even in poor-risk disease. Encouraging data from ibrutinib and venetoclax in Del17p is challenging the notion of disease eradication as the ultimate therapeutic goal to a new concept of merely disease control. By favoring the non-transplant approach, patients should be aware that there are no established salvage therapies, yet, to rescue disease progression after ibrutinib. When disease eradication is the desirable approach, a reduced intensity conditioning allogeneic hematopoietic cell transplant is the preferred choice at this time.
Author List
Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala EAuthor
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenineAllografts
Antibodies, Monoclonal
Antibodies, Neoplasm
Bridged Bicyclo Compounds, Heterocyclic
Chromosome Deletion
Chromosomes, Human, Pair 17
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Piperidines
Proto-Oncogene Proteins c-bcl-2
Pyrazoles
Pyrimidines
Smith-Magenis Syndrome
Sulfonamides
